Hepatitis C virus (HCV) reinfection and injecting risk behavior following elbasvir (EBR)/grazoprevir (GZR) treatment in participants on opiate agonist therapy (OAT): Co-STAR part B [abstract 195]

Dore G, Grebely J, Altice F, Litwin AH, Dalgard O, Gane E, et al. Hepatitis C virus (HCV) reinfection and injecting risk behavior following elbasvir (EBR)/grazoprevir (GZR) treatment in participants on opiate agonist therapy (OAT): Co-STAR part B [abstract 195]. Presented at the Liver Meeting 2017; October 20–24, 2017; Washington, DC.

Publication Type:

Conference Proceedings

Authors:

Dore, G.; Grebely, J.; Altice, Frederick; Litwin, Alain H.; Dalgard, O.; Gane, E.; Shibolet, O.

Source:

Presented at the Liver Meeting 2017; October 20–24, 2017; Washington, DC (0)

Cited On:

External Third-party Web Link:

http://www.natap.org/2017/AASLD/AASLD_30.htm

Export Citation:
RIS Format
Top